Tag: congenital heart disease chd market report

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Will Be The Estimated Market Size Of The Congenital Heart Disease (CHD) Market By 2030?

The market for congenital heart disease (chd) has experienced robust expansion in recent years. This market is projected to expand from $4.85 billion in 2025 to $5.32 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 9.7%. Historically, this growth was driven by factors such as the significant occurrence of structural birth defects, insufficient early diagnostic tools, the necessity for open-heart surgery, elevated infant mortality rates, and the centralization of treatment within tertiary hospitals.

The market for congenital heart disease (chd) is projected to experience substantial expansion in the coming years. This market is anticipated to reach $7.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. Several factors contribute to this projected increase, including progress in minimally invasive cardiology, enhanced imaging and diagnostic techniques, an expanding adult chd demographic, the proliferation of specialized cardiac facilities, and increased investments in healthcare. Key developments expected during this timeframe involve an uptick in early prenatal and neonatal screening, greater acceptance of catheter-based procedures, the broadening of both pediatric and adult chd care initiatives, improved survival rates fostering adult chd management, and comprehensive, long-term disease management approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

Which Growth Drivers Are Expected To Support The Congenital Heart Disease (CHD) Market Forward?

The rising incidence of maternal diabetes is anticipated to propel the expansion of the congenital heart disease (CHD) market going forward. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is defined as diabetes that develops in women during pregnancy who did not have the condition before conception. This type of diabetes is primarily caused by lifestyle changes, including sedentary behavior and unhealthy dietary habits, as well as a general increase in obesity rates among women of childbearing age. Maternal diabetes can lead to congenital heart disease (CHD) in infants because high blood sugar levels detrimentally affect fetal heart development. Specifically, elevated glucose concentrations in the mother’s blood can disrupt the normal formation of the baby’s heart, thereby increasing the risk of CHD. For instance, in November 2025, the Society For Maternal Fetal Medicine, a US-based organization, stated that gestational diabetes mellitus (GDM) affects approximately 15.6% of women worldwide, with an estimated 23.3 million live births impacted by hyperglycemia during pregnancy in 2024. Consequently, the increasing number of maternal diabetes cases is driving the growth of the congenital heart disease (CHD) market.

How Is The Congenital Heart Disease (CHD) Market Structured Across Different Market Segments?

The congenital heart disease (chd) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

What Trends Are Affecting The Growth Of The Congenital Heart Disease (CHD) Market?

Key companies within the congenital heart disease market are developing non-invasive heart valves to improve patient outcomes and overall quality of life. Non-surgical heart valves, also known as transcatheter valves, are medical devices that treat heart valve conditions without requiring traditional open-heart surgery. For example, in February 2023, Medtronic, a US-based medical technology firm, relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System. This system provides an innovative, minimally invasive alternative to open-heart surgery for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. This particular system stands as the first FDA-approved valve designed for the heart’s right side, offering a non-surgical option for individuals with severe pulmonary valve regurgitation. The Harmony TPV System originally received U.S. FDA approval in 2021. Its reintroduction followed a voluntary recall, highlighting Medtronic’s commitment to advancing solutions for those living with congenital heart disease.

Which Organizations Are Involved In The Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (chd) market are Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, Braile Biomedica

Access The Complete Congenital Heart Disease (CHD) Market Report:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Region Is The Dominant Market In The Congenital Heart Disease (CHD) Market?

North America was the largest region in the congenital heart disease (CHD) market in 2025. The regions covered in the congenital heart disease (chd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Congenital Heart Disease (CHD) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2026, By The Business Research Company

Congenital Heart Disease Chd Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Pheochromocytoma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report

Pituitary Dwarf Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Congenital Heart Disease (CHD) Market Grow Between 2026 And 2030?

The market size for congenital heart disease (chd) has demonstrated robust growth over recent years. It is forecast to increase from $4.85 billion in 2025 to $5.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.7%. This historical expansion can be linked to factors such as the high prevalence of structural birth defects, limited early diagnostic capabilities, a reliance on open-heart surgery, high infant mortality rates, and the concentration of care in tertiary hospitals.

The congenital heart disease (chd) market size is anticipated to undergo significant expansion in the upcoming years. It is projected to climb to $7.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. The expansion over this forecast period stems from various factors, including advancements in minimally invasive cardiology, enhancements in imaging and diagnostics, the expanding adult chd population, the proliferation of specialized cardiac centers, and escalating healthcare investments. Noteworthy trends during the forecast period involve an increase in early prenatal and neonatal screening, a rising acceptance of catheter-based interventions, the broadening of pediatric and adult chd care programs, improved survival rates prompting more adult chd care, and a focus on multidisciplinary long-term disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Drivers Are Supporting The Congenital Heart Disease (CHD) Market Growth?

The increasing incidence of maternal diabetes cases is anticipated to fuel the expansion of the congenital heart disease (CHD) market. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is a condition where diabetes develops during pregnancy in women who were not diabetic before conceiving. This condition often stems from lifestyle modifications, such as sedentary habits and poor dietary choices, coupled with a general rise in obesity rates among women of childbearing age. Maternal diabetes can lead to congenital heart disease (CHD) in infants because elevated blood sugar levels negatively impact fetal heart development. The heightened glucose concentrations in the mother’s bloodstream can disrupt the proper formation of the baby’s heart, thereby increasing the likelihood of CHD. For instance, a report from November 2025 by the Society For Maternal Fetal Medicine, a US-based organisation, indicates that gestational diabetes mellitus (GDM) affects approximately 15.6% of women globally, with an estimated 23.3 million live births impacted by hyperglycemia during pregnancy in 2024. Consequently, the rising number of maternal diabetes cases is a significant factor driving the growth of the congenital heart disease (CHD) market.

What Are The Different Segment Types In The Congenital Heart Disease (CHD) Market Segment Breakdown?

The congenital heart disease (chd) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Which Trends Are Expected To Impact The Congenital Heart Disease (CHD) Market?

Key companies operating in the congenital heart disease market are developing non-surgical heart valves, aiming to improve patient outcomes and their quality of life. These non-surgical, or transcatheter, medical devices address heart valve conditions without the necessity of traditional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. This system presents a groundbreaking, minimally invasive option for patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies, as an alternative to open-heart surgery. It is the first FDA-approved valve specifically designed for the right side of the heart, offering a non-surgical solution for individuals suffering from severe pulmonary valve regurgitation. The Harmony TPV System originally received U.S. FDA approval in 2021 and was reintroduced following a voluntary recall, thereby demonstrating Medtronic’s commitment to advancing solutions for congenital heart disease patients.

Who Are The Well-Known Companies In The Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (chd) market are Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, Braile Biomedica

Get The Full Congenital Heart Disease (CHD) Market Report:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Where Is The Congenital Heart Disease (CHD) Market Most Concentrated Geographically?

North America was the largest region in the congenital heart disease (CHD) market in 2025. The regions covered in the congenital heart disease (chd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Congenital Heart Disease (CHD) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2026, By The Business Research Company

Pediatric Heart Valve Repair And Replacement Market Report 2026

https://www.thebusinessresearchcompany.com/report/pediatric-heart-valve-repair-and-replacement-global-market-report

Congenital Heart Defect Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-defect-devices-global-market-report

Cardiometabolic Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Congenital Heart Disease (CHD) Market Grow Between 2026 And 2030?

The market size for congenital heart disease (chd) has demonstrated robust growth over recent years. It is forecast to increase from $4.85 billion in 2025 to $5.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.7%. This historical expansion can be linked to factors such as the high prevalence of structural birth defects, limited early diagnostic capabilities, a reliance on open-heart surgery, high infant mortality rates, and the concentration of care in tertiary hospitals.

The congenital heart disease (chd) market size is anticipated to undergo significant expansion in the upcoming years. It is projected to climb to $7.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. The expansion over this forecast period stems from various factors, including advancements in minimally invasive cardiology, enhancements in imaging and diagnostics, the expanding adult chd population, the proliferation of specialized cardiac centers, and escalating healthcare investments. Noteworthy trends during the forecast period involve an increase in early prenatal and neonatal screening, a rising acceptance of catheter-based interventions, the broadening of pediatric and adult chd care programs, improved survival rates prompting more adult chd care, and a focus on multidisciplinary long-term disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Drivers Are Supporting The Congenital Heart Disease (CHD) Market Growth?

The increasing incidence of maternal diabetes cases is anticipated to fuel the expansion of the congenital heart disease (CHD) market. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is a condition where diabetes develops during pregnancy in women who were not diabetic before conceiving. This condition often stems from lifestyle modifications, such as sedentary habits and poor dietary choices, coupled with a general rise in obesity rates among women of childbearing age. Maternal diabetes can lead to congenital heart disease (CHD) in infants because elevated blood sugar levels negatively impact fetal heart development. The heightened glucose concentrations in the mother’s bloodstream can disrupt the proper formation of the baby’s heart, thereby increasing the likelihood of CHD. For instance, a report from November 2025 by the Society For Maternal Fetal Medicine, a US-based organisation, indicates that gestational diabetes mellitus (GDM) affects approximately 15.6% of women globally, with an estimated 23.3 million live births impacted by hyperglycemia during pregnancy in 2024. Consequently, the rising number of maternal diabetes cases is a significant factor driving the growth of the congenital heart disease (CHD) market.

What Are The Different Segment Types In The Congenital Heart Disease (CHD) Market Segment Breakdown?

The congenital heart disease (chd) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Which Trends Are Expected To Impact The Congenital Heart Disease (CHD) Market?

Key companies operating in the congenital heart disease market are developing non-surgical heart valves, aiming to improve patient outcomes and their quality of life. These non-surgical, or transcatheter, medical devices address heart valve conditions without the necessity of traditional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. This system presents a groundbreaking, minimally invasive option for patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies, as an alternative to open-heart surgery. It is the first FDA-approved valve specifically designed for the right side of the heart, offering a non-surgical solution for individuals suffering from severe pulmonary valve regurgitation. The Harmony TPV System originally received U.S. FDA approval in 2021 and was reintroduced following a voluntary recall, thereby demonstrating Medtronic’s commitment to advancing solutions for congenital heart disease patients.

Who Are The Well-Known Companies In The Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (chd) market are Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, Braile Biomedica

Get The Full Congenital Heart Disease (CHD) Market Report:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Where Is The Congenital Heart Disease (CHD) Market Most Concentrated Geographically?

North America was the largest region in the congenital heart disease (CHD) market in 2025. The regions covered in the congenital heart disease (chd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Congenital Heart Disease (CHD) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2026, By The Business Research Company

Pediatric Heart Valve Repair And Replacement Market Report 2026

https://www.thebusinessresearchcompany.com/report/pediatric-heart-valve-repair-and-replacement-global-market-report

Congenital Heart Defect Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-defect-devices-global-market-report

Cardiometabolic Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Congenital Heart Disease (CHD) Market Grow Between 2026 And 2030?

The market size for congenital heart disease (chd) has demonstrated robust growth over recent years. It is forecast to increase from $4.85 billion in 2025 to $5.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.7%. This historical expansion can be linked to factors such as the high prevalence of structural birth defects, limited early diagnostic capabilities, a reliance on open-heart surgery, high infant mortality rates, and the concentration of care in tertiary hospitals.

The congenital heart disease (chd) market size is anticipated to undergo significant expansion in the upcoming years. It is projected to climb to $7.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. The expansion over this forecast period stems from various factors, including advancements in minimally invasive cardiology, enhancements in imaging and diagnostics, the expanding adult chd population, the proliferation of specialized cardiac centers, and escalating healthcare investments. Noteworthy trends during the forecast period involve an increase in early prenatal and neonatal screening, a rising acceptance of catheter-based interventions, the broadening of pediatric and adult chd care programs, improved survival rates prompting more adult chd care, and a focus on multidisciplinary long-term disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Drivers Are Supporting The Congenital Heart Disease (CHD) Market Growth?

The increasing incidence of maternal diabetes cases is anticipated to fuel the expansion of the congenital heart disease (CHD) market. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is a condition where diabetes develops during pregnancy in women who were not diabetic before conceiving. This condition often stems from lifestyle modifications, such as sedentary habits and poor dietary choices, coupled with a general rise in obesity rates among women of childbearing age. Maternal diabetes can lead to congenital heart disease (CHD) in infants because elevated blood sugar levels negatively impact fetal heart development. The heightened glucose concentrations in the mother’s bloodstream can disrupt the proper formation of the baby’s heart, thereby increasing the likelihood of CHD. For instance, a report from November 2025 by the Society For Maternal Fetal Medicine, a US-based organisation, indicates that gestational diabetes mellitus (GDM) affects approximately 15.6% of women globally, with an estimated 23.3 million live births impacted by hyperglycemia during pregnancy in 2024. Consequently, the rising number of maternal diabetes cases is a significant factor driving the growth of the congenital heart disease (CHD) market.

What Are The Different Segment Types In The Congenital Heart Disease (CHD) Market Segment Breakdown?

The congenital heart disease (chd) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Which Trends Are Expected To Impact The Congenital Heart Disease (CHD) Market?

Key companies operating in the congenital heart disease market are developing non-surgical heart valves, aiming to improve patient outcomes and their quality of life. These non-surgical, or transcatheter, medical devices address heart valve conditions without the necessity of traditional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. This system presents a groundbreaking, minimally invasive option for patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies, as an alternative to open-heart surgery. It is the first FDA-approved valve specifically designed for the right side of the heart, offering a non-surgical solution for individuals suffering from severe pulmonary valve regurgitation. The Harmony TPV System originally received U.S. FDA approval in 2021 and was reintroduced following a voluntary recall, thereby demonstrating Medtronic’s commitment to advancing solutions for congenital heart disease patients.

Who Are The Well-Known Companies In The Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (chd) market are Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, Braile Biomedica

Get The Full Congenital Heart Disease (CHD) Market Report:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Where Is The Congenital Heart Disease (CHD) Market Most Concentrated Geographically?

North America was the largest region in the congenital heart disease (CHD) market in 2025. The regions covered in the congenital heart disease (chd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Congenital Heart Disease (CHD) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2026, By The Business Research Company

Pediatric Heart Valve Repair And Replacement Market Report 2026

https://www.thebusinessresearchcompany.com/report/pediatric-heart-valve-repair-and-replacement-global-market-report

Congenital Heart Defect Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-defect-devices-global-market-report

Cardiometabolic Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Congenital Heart Disease (CHD) Market Projected To Become By 2030 Based On Its 2026 Valuation?

The congenital heart disease (chd) market has seen substantial growth over recent years. It is anticipated to expand from $4.85 billion in 2025 to $5.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.7%. Historically, this growth can be ascribed to a high incidence of structural birth defects, restricted early diagnostic abilities, the predominant use of open-heart surgery, elevated infant mortality rates, and the concentration of healthcare services in specialized tertiary hospitals.

The congenital heart disease (chd) market size is anticipated to experience substantial expansion over the forthcoming years. It is projected to reach $7.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. This growth during the forecast period can be ascribed to advancements in minimally invasive cardiology, enhanced imaging and diagnostics, an increasing adult chd population, the proliferation of specialized cardiac centers, and escalating healthcare investments. Key trends anticipated for this period encompass an increase in early prenatal and neonatal screening, a surge in the adoption of catheter-based interventions, the enlargement of pediatric and adult chd care programs, higher survival rates fueling adult chd care, and comprehensive multidisciplinary long-term disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Congenital Heart Disease (CHD) Market?

The rising incidence of maternal diabetes cases is anticipated to fuel the expansion of the congenital heart disease (CHD) market. Maternal diabetes, also known as gestational diabetes mellitus (GDM), refers to diabetes that emerges during pregnancy in women who did not have the condition before conception. This condition is primarily caused by lifestyle changes, including sedentary behavior and unhealthy dietary habits, coupled with an overall increase in obesity rates among women of childbearing age. Maternal diabetes can lead to congenital heart disease (CHD) in infants because high blood sugar levels affect fetal heart development. The elevated glucose concentrations in the mother’s blood can disrupt the normal development of the baby’s heart, consequently increasing the risk of CHD. For instance, in November 2025, according to the Society For Maternal Fetal Medicine, a US-based organisation, gestational diabetes mellitus (GDM) impacts approximately 15.6% of women worldwide, with an estimated 23.3 million live births affected by hyperglycemia during pregnancy in 2024. Therefore, the growing number of maternal diabetes cases is driving the growth of the congenital heart disease (CHD) market.

What Segment Groups Are Identified Within The Congenital Heart Disease (CHD) Market?

The congenital heart disease (chd) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

What Trends Are Affecting The Expansion Of The Congenital Heart Disease (CHD) Market?

Leading companies within the congenital heart disease market are engaged in the development of non-surgical heart valves, aiming to enhance patient outcomes and their quality of life. These non-surgical heart valves, also known as transcatheter devices, are medical tools designed to treat heart valve conditions without requiring traditional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, brought back its Harmony Transcatheter Pulmonary Valve (TPV) System. This system provides an innovative, minimally invasive alternative to open-heart surgery for patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. It stands as the first FDA-approved valve specifically engineered for the right side of the heart, offering a non-surgical approach for individuals experiencing severe pulmonary valve regurgitation. The U.S. FDA initially approved the Harmony TPV System in 2021, and its reintroduction after a voluntary recall highlights Medtronic’s unwavering commitment to advancing solutions for congenital heart disease patients.

Which Companies Hold Significant Positions In The Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (chd) market are Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, Braile Biomedica

Read the full congenital heart disease (chd) market report here:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Regions Are Projected To Dominate The Congenital Heart Disease (CHD) Market In The Coming Years?

North America was the largest region in the congenital heart disease (CHD) market in 2025. The regions covered in the congenital heart disease (chd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Congenital Heart Disease (CHD) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2026, By The Business Research Company

Congenital Heart Disease Chd Global Market Report

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Pheochromocytoma Global Market Report

https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report

Pituitary Dwarf Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model